

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

January 12, 2024

Zhengbin (Bing) Yao, Ph.D. Chief Executive Officer ArriVent Biopharma, Inc. 18 Campus Boulevard, Suite 100 Newtown Square, PA 19073

> Re: ArriVent Biopharma, Inc. Registration Statement on Form S-1 Filed January 5, 2024 File No. 333-276397

Dear Zhengbin (Bing) Yao:

We have reviewed your registration statement and have the following comment.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments.

## Form S-1 filed January 5, 2024

Management's Discussion and Analysis of Financial Condition and Results of Operations Determination of Fair Value of Our Common Stock, page 108

1. We note your response to prior comment eight, as well as your disclosure related to options granted on January 1 and January 4, 2024 on page 108. Please revise this section to discuss how the estimated fair value per common share on grant date for these options compare to the low end and midpoint of estimated price range when available. Revise to identify the extent to which any incremental increase in value between the grant date and the date of the filing is due to specific and identifiable business activities or events.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Zhengbin (Bing) Yao, Ph.D. ArriVent Biopharma, Inc. January 12, 2024 Page 2

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Li Xiao at 202-551-4391 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Please contact Chris Edwards at 202-551-6761 or Suzanne Hayes at 202-551-3675 with any other questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: John Rudy